newsfilter
← Latest News
GlobeNewswire·

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

100% complete response ("CR") rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1)Favorable safety